Table 2.
Comparison of mortality and duration of hospitalization between global cohorts and our study.
| Cohort | Rotterdam | EHFS I | EHFS II | EFFECT | ADHERE | OPTIMIZE-HF | ATTEND | THESUS-HF | ALARM-HF | ASIAN-HF | VHFR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients number | 7983 | 11327 | 3580 | 2450 | 105388 | 48612 | 4842 | 1006 | 4953 | 5276 | 572 |
| In-hospital mortality, % | 6.90% | 6.70% | 4% | 4% | 6.40% | 4.20% | 11% | 13.25% | |||
| 30-day mortality, % | 14% | 6.40% | 4% | 11.20% | 27.3% | ||||||
| 60-day mortality, % | 9% (60–90 days) | 10.60% | |||||||||
| 90-day mortality, % | 6.60% | 8.10% | 32.53% | ||||||||
| 180-day mortality, % | 17.80% | 6.9% | 38.15% | ||||||||
| 1-year mortality, % | 37% | 20.50% | 24.20% | ||||||||
| Hospital stay, median days | 11 | 9 | 4 | 4 | 21 | 7 | 6 | 8 |
Rotterdam: The prognosis of heart failure in the general population: The Rotterdam Study, EHFS I, EuroHeart Failure Survey I; EHFS II, Euro Heart Failure Survey II; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; ADHERE, Acute Decompensated Heart Failure National Registry; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; ATTEND, Acute decompensated heart failure syndromes registry; THESUS-HF, The Sub-Saharan Africa Survey of Heart Failure; ALARM-HF, Acute Heart Failure Global Survey of Standard Treatment; ASIAN-HF, Asian heart failure registry; VHFR, Vellore Heart Failure Registry.